Skip to main content
SpringerLink
Log in

Perindopril versus Angiotensin II Receptor Blockade in Hypertension and Coronary Artery Disease

Implications of Clinical Trials

  • Review Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

The renin-angiotensin-aldosterone system (RAAS) is now known to play a key role in the pathogenesis of hypertension and a range of other cardiovascular diseases. Two groups of drugs, the ACE inhibitors and angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]) have been developed with the aim of improving clinical outcomes by regulating the RAAS in patients with cardiovascular disease.

Initial assumptions were that these two drug types might be interchangeable, but ongoing research has revealed differences between them in terms of pharmacology and outcomes in clinical trials. Although both groups of drugs lower blood pressure, studies of the ACE inhibitor perindopril have revealed preservation of beneficial vascular and endothelial effects mediated by bradykinin and nitric oxide. The selective blockade exerted by ARBs is not associated with these effects. Furthermore, examination of clinical endpoints in major clinical trials has provoked discussion about outcomes comparing ACE inhibitors and ARBs, with recent debate focusing on the incidence of myocardial infarction (MI) in patients receiving these agents. Whether there is an actual difference in protection from MI remains unresolved, although available data confirm the benefit and safety of ACE inhibitors, in particular perindopril, for myocardial protection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Table II
Fig. 3

Similar content being viewed by others

References

  1. Ferrari R. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert Rev Cardiovasc Ther 2005; 3: 15–29

    Article  PubMed  CAS  Google Scholar 

  2. Lévy BI. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation 2004; 109: 8–13

    Article  PubMed  Google Scholar 

  3. Schiffrin EL, Touyz RM. From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. Am J Physiol Heart Circ Physiol 2004; 287: H435–H446

    Article  PubMed  CAS  Google Scholar 

  4. Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999; 33: 613–21

    Article  PubMed  CAS  Google Scholar 

  5. Matsubara H. Pathophysiological role of angiotensin II type 2 receptors in cardiovascular and renal diseases. Circ Res 1998; 83: 1182–91

    Article  PubMed  CAS  Google Scholar 

  6. Siragy HM. The role of the AT2 receptor in hypertension. Am J Hypertens 2000; 13 (Suppl. 5 Pt 2): 62S–67S

    Article  PubMed  CAS  Google Scholar 

  7. Carey RM, Wang Z-Q, Siragy HM. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 2000; 35: 155–63

    Article  PubMed  CAS  Google Scholar 

  8. Carey RM, Jin XH, Siragy HM. Role of the angiotensin AT2 receptor in blood pressure regulation and therapeutic implications. Am J Hypertens 2001; 14 (Suppl. 6 Pt 2): 98S–102S

    Article  PubMed  CAS  Google Scholar 

  9. Strauss MH, Lonn EM, Verma S. Is the jury out? Class specific differences on coronary outcomes with ACE-inhibitors and ARBs: insight from meta-analysis and The Blood Pressure Lowering Treatment Trialists’ Collaboration. Eur Heart J 2005; 26: 2351–3

    Article  PubMed  CAS  Google Scholar 

  10. Verdecchia P, Angeli F, Gattobigio R, et al. Do angiotensin II receptor blockers increase the risk of myocardial infarction? Eur Heart J 2005; 26: 2381–6

    Article  PubMed  CAS  Google Scholar 

  11. Alfakih K, Maqbool A, Sivananthan M, et al. Left ventricle mass index and the common, functional, X-linked angiotensin II type-2 receptor gene polymorphism (−1332 G/A) in patients with systemic hypertension. Hypertension 2004; 43: 1189–94

    Article  PubMed  CAS  Google Scholar 

  12. Bertrand ME. Provision of cardiovascular protection by ACE inhibitors: a review of recent trials. Curr Med Res Opin 2004; 20: 1559–69

    Article  PubMed  CAS  Google Scholar 

  13. Ichihara S, Senbonmatsu T, Price E Jr, et al. Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation 2001; 104: 346–51

    Article  PubMed  CAS  Google Scholar 

  14. López-Sendón J, Swedberg K, McMurray J, et al. Task Force on ACE-inhibitors of the European Society of Cardiology: expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. Eur Heart J 2004; 25: 1454–70

    Article  PubMed  Google Scholar 

  15. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial —the Losartan Heart Failure Survival Study, ELITE II. Lancet 2000; 355: 1582–7

    Article  PubMed  CAS  Google Scholar 

  16. Dickstein K, Kjekshus J. OPTIMAAL Steering Committee of the OPTIMAAL Study Group: effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial —Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752–60

    Article  PubMed  CAS  Google Scholar 

  17. Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction [letter]. BMJ 2004; 329: 1248–9

    Article  PubMed  Google Scholar 

  18. McDonald MA, Simpson SH, Ezekowitz JA, et al. Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ 2005; 331: 873–78

    Article  PubMed  CAS  Google Scholar 

  19. Cheung BMY, Cheung GTY, Lauder IJ, et al. Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension. J Hum Hypertens 2006; 20: 37–43

    Article  PubMed  CAS  Google Scholar 

  20. Granger CB, McMurray JJ, Yusuf S, et al. CHARM Investigators and Committees: effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors —the CHARM-Alternative trial. Lancet 2003; 362: 772–6

    Article  PubMed  CAS  Google Scholar 

  21. McMurray JJ, Ostergren J, Swedberg K, et al. CHARM Investigators and Committees: effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors —the CHARM-Added trial. Lancet 2003; 362: 767–71

    Article  PubMed  CAS  Google Scholar 

  22. Yusuf S, Pfeffer MA, Swedberg K, et al. CHARM Investigators and Committees: effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction —the CHARM-Preserved Trial. Lancet 2003; 362: 777–81

    Article  PubMed  CAS  Google Scholar 

  23. Bussien JP, d’Amore TF, Perret L, et al. Single and repeated dosing of the converting enzyme inhibitor perindopril to normal subjects. Clin Pharmacol Ther 1986; 39: 554–8

    Article  PubMed  CAS  Google Scholar 

  24. Zhuo JL, Mendelsohn FAO, Ohishi M. Perindopril alters vascular angiotensin-converting enzyme, AT1 receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension 2002; 39: 634–8

    Article  PubMed  CAS  Google Scholar 

  25. Su JB, Barbe F, Crozatier B, et al. Increased bradykinin levels accompany the hemodynamic response to acute inhibition of angiotensin-converting enzyme in dogs with heart failure. J Cardiovasc Pharmacol 1999; 34: 700–10

    Article  PubMed  CAS  Google Scholar 

  26. Pellacani A, Brunner HR, Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin Sci (Lond) 1994; 87: 567–74

    CAS  Google Scholar 

  27. Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994; 23: 439–49

    Article  PubMed  CAS  Google Scholar 

  28. EUROPA Investigators. The European Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease Investigators: efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease —randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–8

    Article  Google Scholar 

  29. Ferrari R. PERTINENT: PERindopril, Thrombosis, InflammatioN, Endothelial dysfunction and Neurohormonal activation Trial, a sub-analysis of EUROPA [abstract 2585]. Annual Congress of the European Society of Cardiology. 2004; Aug 28–Sep 1: Munich, Germany

  30. Safar ME, London GM, Plante GE. Arterial stiffness and kidney function. Hypertension 2004; 43: 163–8

    Article  PubMed  CAS  Google Scholar 

  31. Tropeano AI, Boutouyrie P, Pannier B, et al. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension 2006; 48: 80–6

    Article  PubMed  CAS  Google Scholar 

  32. Asmar RG, Pannier B, Santoni JP, et al. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. Circulation 1988; 78: 941–50

    Article  PubMed  CAS  Google Scholar 

  33. Kool MJ, Lustermans FA, Breed JG, et al. The influence of perindopril and the diuretic combination amiloride + hydrochlorothiazide on the vessel wall properties of large arteries in hypertensive patients. J Hypertens 1995; 13: 839–48

    Article  PubMed  CAS  Google Scholar 

  34. Thybo NK, Stephens N, Cooper A, et al. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 1995; 25 (4 Pt 2): 474–81

    Article  PubMed  CAS  Google Scholar 

  35. Buus NH, Bøttcher M, Jørgensen CG, et al. Myocardial perfusion during long-term angiotensin-converting enzyme inhibition or β-blockade in patients with essential hypertension. Hypertension 2004; 44: 465–70

    Article  PubMed  CAS  Google Scholar 

  36. Schwartzkopff B, Brehm M, Mundhenke M, et al. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension 2000; 36: 220–5

    Article  PubMed  CAS  Google Scholar 

  37. Guerin AP, Blacher J, Pannier B, et al. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001; 103: 987–92

    Article  PubMed  CAS  Google Scholar 

  38. Hui Y, Dai Z, Chen X, et al. Effect of perindopril and metoprolol on left ventricular hypertrophy and performance in essential hypertension. Chin Med J (Engl) 1995; 108: 678–81

    PubMed  CAS  Google Scholar 

  39. Ferrari R. Perindopril and Remodeling in Elderly with Acute Myocardial Infarction Investigators: effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome —results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) study. Arch Intern Med 2006; 166: 659–66

    Article  PubMed  CAS  Google Scholar 

  40. Ghiadoni L, Magagna A, Versari D, et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003; 41: 1281–6

    Article  PubMed  CAS  Google Scholar 

  41. Fennessy PA, Campbell JH, Mendelsohn FA, et al. Angiotensin-converting enzyme inhibitors and atherosclerosis: relevance of animal models to human disease. Clin Exp Pharmacol Physiol 1996; 23: S30–2

    Article  PubMed  CAS  Google Scholar 

  42. Ferrari R. Effect of ACE inhibition on myocardial ischaemia. Eur Heart J 1998; 19Suppl. J: J30–5

    PubMed  CAS  Google Scholar 

  43. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required plus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906

    Article  PubMed  Google Scholar 

  44. Hansson L, Hedner T, Dahlof B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Blood Press 1992; 1(2): 113–9

    Article  PubMed  CAS  Google Scholar 

  45. Curran MP, McCormack PL, Simpson D. Perindopril: a review of its use in patients with or at risk of developing coronary artery disease. Drugs 2006; 66: 235–56

    Article  PubMed  CAS  Google Scholar 

  46. Poulter NR, Wedel H, Dahlöf B, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907–13

    Article  PubMed  CAS  Google Scholar 

  47. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97

    Article  Google Scholar 

  48. Dagenais GR, Pogue J, Fox K, et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006; 368: 581–8

    Article  PubMed  CAS  Google Scholar 

  49. Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus: atherosclerosis risk in communities study. N Engl J Med 2000; 342: 905–12

    Article  PubMed  CAS  Google Scholar 

  50. Gupta AK. Determinants of new onset diabetes among hypertensive patients randomized in the ASCOT-BPLA trial [abstract]. World Congress of Cardiology; 2006 Sep 2–6, Barcelona

  51. Dahlöf B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003

    Article  PubMed  Google Scholar 

  52. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545–53

    Article  PubMed  CAS  Google Scholar 

  53. Julius S, Kjeldsen SE, Weber M, et al. for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31

    Article  PubMed  CAS  Google Scholar 

  54. Lithell H, Hansson L, Skoog I, et al. SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–86

    Article  PubMed  CAS  Google Scholar 

  55. McMurray J, Solomon S, Pieper K, et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 2006; 47: 726–33

    Article  PubMed  CAS  Google Scholar 

  56. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–906

    Article  PubMed  CAS  Google Scholar 

  57. Volpe M, Mancia G, Trimarco B. Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. J Hypertens 2005; 23: 2113–8

    Article  PubMed  CAS  Google Scholar 

  58. Epstein BJ, Gums JG. Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations. Ann Pharmacother 2005; 39: 470–80

    Article  PubMed  CAS  Google Scholar 

  59. Turnbull F. New evidence of blood pressure-independent effects for agents acting via the renin-angiotensin system: analyses from the Blood Pressure Lowering Treatment Trialists’ Collaboration [abstract]. Program and abstracts from the Fifteenth European Meeting on Hypertension, June 17–21, 2005, Milan, Italy

  60. Zhang H, Thijs L, Staessen JA. Blood pressure lowering for primary and secondary prevention of stroke. Hypertension 2006; 48: 187–95

    Article  PubMed  CAS  Google Scholar 

  61. Strauss MH, Hall A. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 2006; 114: 838–54

    Article  PubMed  Google Scholar 

  62. National Institute for Health and Clinical Excellence (NICE). Hypertension: management of hypertension in adults in primary care (partial update). NICE guideline: draft for consultation. London: February 2006 [online]. Available from URL: http://www.nice.org.uk/pdf/Hypertension_update_NICE_0206.pdf [Accessed 2006 Nov 17]

  63. National Institute for Clinical Excellence (NICE). Hypertension: management of hypertension in adults in primary care. Clinical guideline 18. London: August 2004 [online]. Available from URL: http://www.nice.org.uk/pdf/CG018fullguideline.pdf [Accessed 2006 Nov 17]

  64. US Dept of Health and Human Services. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood pressure. National Institutes of Health, National Heart, Lung, and Blood Institute National High Blood pressure Education Program. NIH Publication No. 04-5230, August 2004 [online]. Available from URL: http://www.nhbli.nih.gov/guidelines/hypertension/jnc7full.pdf [Accessed 2006 Nov 17]

  65. PROGRESS Collaborative Group. Effects of a perindoprilbased blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J 2003; 24: 475–84

    Google Scholar 

Download references

Acknowledgements

Preparation of this manuscript was supported by Servier. Editorial assistance was provided by WK Health Medical Communications.

Author information

Authors and Affiliations

  1. Department of Medical Cardiology, Glasgow Royal Infirmary, 10 Alexandra Parade, Glasgow, G31 2ER, Scotland

    Adrian J. B. Brady

Authors
  1. Adrian J. B. Brady
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brady, A.J.B. Perindopril versus Angiotensin II Receptor Blockade in Hypertension and Coronary Artery Disease. Clin. Drug Investig. 27, 149–161 (2007). https://doi.org/10.2165/00044011-200727030-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200727030-00001

Keywords

Search

Navigation